Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study

Background: Cytoreductive therapies have been the standard treatment for patients with high-risk polycythemia vera (PV) for decades. However, approximately 24% of patients treated with hydroxyurea will eventually develop resistance or intolerance to hydroxyurea and need second-line (2L) therapy. Obj...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Steffen Koschmieder, Clemens Schulte, Eyck von der Heyde, Lambert Busque, Françoise Boyer-Perrard, Timothy Devos, Francesco Passamonti, Wendy Y. Cheng, Mu Cheng, Marja Nuortti, Volker Baum, Claire Harrison
Format:	Artigo
Sprog:	Inglês
Udgivet:	SAGE Publishing 2025-07-01
Serier:	Therapeutic Advances in Hematology
Online adgang:	https://doi.org/10.1177/20406207251342199
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!